FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946017> ?p ?o ?g. }

• W4361946017 abstract "<div>Abstract<p><b>Background:</b> Endocrine therapy (ET) fails to induce a response in one half of patients with hormone receptor (HR)–positive metastatic breast cancer (MBC), and almost all will eventually become refractory to ET. Circulating tumor cells (CTC) are associated with worse prognosis in patients with MBC, but enumeration alone is insufficient to predict the absolute odds of benefit from any therapy, including ET. We developed a multiparameter CTC-Endocrine Therapy Index (CTC-ETI), which we hypothesize may predict resistance to ET in patients with HR-positive MBC.</p><p><b>Methods:</b> The CTC-ETI combines enumeration and CTC expression of four markers: estrogen receptor (ER), B-cell lymphoma 2 (BCL-2), Human Epidermal Growth Factor Receptor 2 (HER2), and Ki67. The CellSearch System and reagents were used to capture CTC and measure protein expression by immunofluorescent staining on CTC.</p><p><b>Results:</b> The feasibility of determining CTC-ETI was initially established <i>in vitro</i> and then in a prospective single-institution pilot study in patients with MBC. CTC-ETI was successfully determined in 44 of 50 (88%) patients. Eighteen (41%), 9 (20%), and 17 (39%) patients had low, intermediate, and high CTC-ETI scores, respectively. Interobserver concordance of CTC-ETI determination was from 94% to 95% (Kappa statistic, 0.90–0.91). Inter- and cell-to-cell intrapatient heterogeneity of expression of each of the CTC markers was observed. CTC biomarker expression was discordant from both primary and metastatic tissues.</p><p><b>Conclusions:</b> CTC expression of ER, BCL-2, HER2, and Ki67 can be reproducibly measured with high analytical validity using the CellSearch System. The clinical implications of CTC-ETI, and of the heterogeneity of CTC biomarker expression, are being evaluated in an ongoing prospective trial. <i>Clin Cancer Res; 21(11); 2487–98. ©2014 AACR</i>.</p><p><i>See related commentary by Mathew et al., p. 2421</i></p></div>" @default.
• W4361946017 created "2023-04-05" @default.
• W4361946017 creator A5001440314 @default.
• W4361946017 creator A5023947476 @default.
• W4361946017 creator A5029625450 @default.
• W4361946017 creator A5030234836 @default.
• W4361946017 creator A5030296606 @default.
• W4361946017 creator A5035137850 @default.
• W4361946017 creator A5036507987 @default.
• W4361946017 creator A5037856511 @default.
• W4361946017 creator A5046583009 @default.
• W4361946017 creator A5051321803 @default.
• W4361946017 creator A5052071953 @default.
• W4361946017 creator A5060399433 @default.
• W4361946017 creator A5062446153 @default.
• W4361946017 creator A5063496318 @default.
• W4361946017 creator A5069748055 @default.
• W4361946017 creator A5086367318 @default.
• W4361946017 date "2023-03-31" @default.
• W4361946017 modified "2023-09-25" @default.
• W4361946017 title "Data from Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer" @default.
• W4361946017 doi "https://doi.org/10.1158/1078-0432.c.6524091" @default.
• W4361946017 hasPublicationYear "2023" @default.
• W4361946017 type Work @default.
• W4361946017 citedByCount "0" @default.
• W4361946017 crossrefType "posted-content" @default.
• W4361946017 hasAuthorship W4361946017A5001440314 @default.
• W4361946017 hasAuthorship W4361946017A5023947476 @default.
• W4361946017 hasAuthorship W4361946017A5029625450 @default.
• W4361946017 hasAuthorship W4361946017A5030234836 @default.
• W4361946017 hasAuthorship W4361946017A5030296606 @default.
• W4361946017 hasAuthorship W4361946017A5035137850 @default.
• W4361946017 hasAuthorship W4361946017A5036507987 @default.
• W4361946017 hasAuthorship W4361946017A5037856511 @default.
• W4361946017 hasAuthorship W4361946017A5046583009 @default.
• W4361946017 hasAuthorship W4361946017A5051321803 @default.
• W4361946017 hasAuthorship W4361946017A5052071953 @default.
• W4361946017 hasAuthorship W4361946017A5060399433 @default.
• W4361946017 hasAuthorship W4361946017A5062446153 @default.
• W4361946017 hasAuthorship W4361946017A5063496318 @default.
• W4361946017 hasAuthorship W4361946017A5069748055 @default.
• W4361946017 hasAuthorship W4361946017A5086367318 @default.
• W4361946017 hasBestOaLocation W43619460172 @default.
• W4361946017 hasConcept C121608353 @default.
• W4361946017 hasConcept C126322002 @default.
• W4361946017 hasConcept C143998085 @default.
• W4361946017 hasConcept C2779013556 @default.
• W4361946017 hasConcept C530470458 @default.
• W4361946017 hasConcept C61238886 @default.
• W4361946017 hasConcept C71924100 @default.
• W4361946017 hasConceptScore W4361946017C121608353 @default.
• W4361946017 hasConceptScore W4361946017C126322002 @default.
• W4361946017 hasConceptScore W4361946017C143998085 @default.
• W4361946017 hasConceptScore W4361946017C2779013556 @default.
• W4361946017 hasConceptScore W4361946017C530470458 @default.
• W4361946017 hasConceptScore W4361946017C61238886 @default.
• W4361946017 hasConceptScore W4361946017C71924100 @default.
• W4361946017 hasLocation W43619460171 @default.
• W4361946017 hasLocation W43619460172 @default.
• W4361946017 hasOpenAccess W4361946017 @default.
• W4361946017 hasPrimaryLocation W43619460171 @default.
• W4361946017 hasRelatedWork W2006173697 @default.
• W4361946017 hasRelatedWork W2144318661 @default.
• W4361946017 hasRelatedWork W2224319365 @default.
• W4361946017 hasRelatedWork W2365364931 @default.
• W4361946017 hasRelatedWork W2395906155 @default.
• W4361946017 hasRelatedWork W2418638721 @default.
• W4361946017 hasRelatedWork W2979892935 @default.
• W4361946017 hasRelatedWork W3109508423 @default.
• W4361946017 hasRelatedWork W377899687 @default.
• W4361946017 hasRelatedWork W4289745076 @default.
• W4361946017 isParatext "false" @default.
• W4361946017 isRetracted "false" @default.
• W4361946017 workType "article" @default.